Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach
Author
Fuggle, NicholasBere, Nathalie
Bruyère, Olivier
Rosa, Mario Manuel
Prieto Yerro, María Concepción
Dennison, Elaine
Dincer, Fitnat
Gabay, Cem
Haugen, Ida K.
Herrero-Beaumont, Gabriel
Hiligsmann, Mickaël
Hochberg, Marc C.
Laslop, Andrea
Matijevic, Radmila
Maheu, Emmanuel
Migliore, Alberto
Pelletier, Jean Pierre
Radermecker, Régis Pierre
Rannou, François
Uebelhart, Brigitte
Uebelhart, Daniel
Veronese, Nicola
Vlaskovska, Mila
Rizzoli, René
Mobasheri, Ali
Cooper, Cyrus
Reginster, Jean Yves
Date
2022-01-01Journal
Aging Clinical and Experimental ResearchPublisher
Springer NatureType
Article
Metadata
Show full item recordAbstract
Hand osteoarthritis is the most common joint condition and is associated with significant morbidity. It is of paramount importance that patients are thoroughly assessed and examined when complaining of hand stiffness, pain, deformity or disability and that the patient’s concerns and expectations are addressed by the healthcare professional. In 2019 the American College of Rheumatology and Arthritis Foundation (ACR/AF) produced guidelines which included recommendations for the treatment of hand osteoarthritis. An ESCEO expert working group (including patients) was convened and composed this paper with the aim to assess whether these guidelines were appropriate for the treatment of hand osteoarthritis therapy in Europe and whether they met with the ESCEO patient-centered approach. Indeed, patients are the key stakeholders in healthcare and eliciting the patient’s preference is vital in the context of an individual consultation but also for informing research and policy-making. The patients involved in this working group emphasised the often-neglected area of aesthetic changes in hand osteoarthritis, importance of developing pharmacological therapies which can alleviate pain and disability and the need of the freedom to choose which approach (out of pharmacological, surgical or non-pharmacological) they wished to pursue. Following robust appraisal, it was recommended that the ACR/AF guidelines were suitable for a European context (as described within the body of the manuscript) and it was emphasised that patient preferences are key to the success of individual consultations, future research and future policy-making.Sponsors
AmgenIdentifier to cite or link to this item
http://hdl.handle.net/10713/19463ae974a485f413a2113503eed53cd6c53
10.1007/s40520-022-02176-y